Back to Noidecs or All Bud/Flower

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This page was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Terpene Profile (Strain Estimate)

LimoneneMajorCitrus/Sour177℃
CaryophylleneMajorPepper/Spice119℃
LinaloolMajorFloral/Spice198℃

MedBud currently tracks 16 common terpenes, more will be added.

No official terpene profile has been provided for this product, information above is estimated based on public strain information.

Dosing Look-Up Table (Estimated)

0.01/g1.9/mg THCTrace CBD
0.05/g9.5/mg THCTrace CBD
0.1/g19/mg THCTrace CBD
0.15/g28.5/mg THCTrace CBD
0.2/g38/mg THCTrace CBD
0.25/g47.5/mg THCTrace CBD
0.3/g57/mg THCTrace CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
United Kingdom Noidecs
Designation
T19
Cultivar/Strain
Mazar-i-Sharif
Classification
Indica
Chemotype
Type I: High THC
Flower Provided
Trimmed Whole Flower
THC Potential Range (±10%)
17.1-20.9%
CBD Potential Range (±10%)
<1%
Cultivated/Produced by
Australia ECS Botanics
Cultivated or Packaged in
Flag of Australia Australia
Irradiation
Gamma-Irradiated
Imported by
United Kingdom Eaststone
Imported as
Schedule II: Finished Product

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Discontinued

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Dispensing Patient Pharmacies

Product DescriptionPatient Reviews

About Mazar-i-Sharif

MazIndica

Originally called simply "Afghan Skunk" after its parents, a landrace Afghanistan Indica and the well loved Skunk #1, it was renamed Mazar in 1997.

Dutch Flag Dutch Bred, Afghani Flag Afghani Genetics

Mazar, a mostly Indica strain created by Dutch Passion, takes its name from Mazar-i-Sharif, a growing centre for cannabis in Afghanistan.

The smoke of this strain tastes of hash, fruit, citrus, and flowers. Its THC count reaches nearly 20% when the strain is grown properly. Users can experience the world in a bright and psychedelic light after using this strain, or they can fall into a deep sleep.

For most, this strain can be good for nighttime relief of insomnia as well as stimulation of appetite and easing of chronic pain. Mazar may also be prescribed for anxiety, stress, depression, bipolar disorder, and ADD/ADHD. Some find that it helps mitigate the symptoms of Alzheimer's disease, migraines, and headaches.

Since Mazar usually finishes flowering around the first week of November, the strain is better suited for an indoor grow. Inside, the strain will flower between eight and nine weeks and reach about a meter in height. Particularly well suited for the Screen of Green method, these plants will need to be supported during the flowering period.

Description provided by Wikileaf.

Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

United Kingdom About Lyphe Group Ltd

Noidecs Logo

From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.

At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

lyphegroup.com

  Information provided is partially -sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)